Castle Biosciences Aktie [WKN DE: A2PNH3 / ISIN: US14843C1053]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Castle Biosciences Inc Registered Shs

21.09.22		Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference (Businesswire)
20.09.22		Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day (Businesswire)
13.09.22		Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association (Businesswire)
01.09.22		Castle Biosciences to Participate in Upcoming Investor Conferences (Businesswire)
24.08.22		Castle Biosciences to Host Investor Day on Sept. 20, 2022 (Businesswire)
04.08.22		American Gastroenterological Association (AGA) Clinical Practice Update States That TissueCypher® May Be Beneficial for Risk-Stratification of Patients with Non-Dysplastic Barrett’s Esophagus (Businesswire)
03.08.22		Castle Biosciences to Present at the Canaccord Genuity 42nd Annual Growth Conference (Businesswire)
25.07.22		Castle Biosciences to Release Second Quarter 2022 Financial Results and Host Conference Call on Monday, August 8 (Businesswire)
25.07.22		DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma (Businesswire)
20.07.22		Presentation at 2022 AAD Innovation Academy to Showcase the Risk Stratification of DecisionDx®-Melanoma and its Role in the Management of Patients with Cutaneous Melanoma (Businesswire)
18.07.22		Castle Biosciences Honored with a 2022 Arizona Top Workplace Award (Businesswire)
23.06.22		Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study Conducted In Collaboration with the Melanoma Research Foundation’s CURE OM Initiative (Businesswire)
22.06.22		Castle Adds to Evidence Supporting Its Skin Cancer Test Portfolio through Multiple Data Presentations at the SDPA Annual Summer Dermatology Conference 2022 (Businesswire)
20.06.22		Castle Biosciences Announces Support for OHSU’s War on Melanoma™ (Businesswire)
14.06.22		Collaborative Study with Melanoma Research Foundation Confirms Patients Diagnosed with Melanoma Desire Testing with DecisionDx®-Melanoma (Businesswire)
08.06.22		Castle Biosciences to Present at the JMP Securities Life Sciences Conference (Businesswire)
01.06.22		The Castle Story... (RTTNews)
27.05.22		Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award (Businesswire)
25.05.22		Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting (Businesswire)
24.05.22		TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia (Businesswire)
20.05.22		Grant From Research to Prevent Blindness and Castle Biosciences Supports Medical Student Research in Ocular Cancer (Businesswire)
19.05.22		Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC (Businesswire)
10.05.22		Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings (Businesswire)
10.05.22		ADCT Awaits Cami Trial Data, CSTL Boosts Revenue Outlook, ANNX To Report HD Trial Data In Q2 (RTTNews)
09.05.22		Castle Biosciences Reports First Quarter 2022 Results (Businesswire)
06.05.22		Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety (Businesswire)
03.05.22		Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives (Businesswire)
29.04.22		Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests (Businesswire)
26.04.22		Castle Biosciences Completes Acquisition of AltheaDx (Businesswire)
25.04.22		Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9 (Businesswire)
21.04.22		Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx®-Melanoma Tested Patients Compared to Untested Patients (Businesswire)
20.04.22		Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress (Businesswire)
18.04.22		Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference (Businesswire)
05.04.22		Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference (Businesswire)
29.03.22		Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS) (Businesswire)
25.03.22		Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making (Businesswire)
11.03.22		Independent Data Presented at Society for Surgical Oncology Conference Demonstrated DecisionDx®-Melanoma Outperforms T-Stage at Identifying Patients with Low Risk of Sentinel Lymph Node Positivity (Businesswire)
01.03.22		Castle Biosciences to Present at Upcoming Investor Conferences (Businesswire)
28.02.22		Castle Biosciences Reports Fourth Quarter and Full-Year 2021 Results (Businesswire)
14.02.22		Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022 (Businesswire)
25.10.21		Pittsburgh Life Sciences Greenhouse Proudly Announces Portfolio Company Cernostics is Being Acquired by Castle Biosciences (PR Newswire)
21.06.21		Castle Biosciences is Listed in the Houston Chronicle’s "CHRON 100” as One of the 100 Most Successful Publicly Traded Companies in Houston (Businesswire)
09.06.21		Castle Biosciences Announces Receipt of New York Laboratory Permit (Businesswire)
24.05.21		Castle Biosciences to Host Ribbon Cutting Ceremony at New Corporate Headquarters (Businesswire)
21.05.21		Castle Biosciences Supports the American Skin Association with Research Grant (Businesswire)
20.05.21		Expert Panel Provides Framework for Incorporating DecisionDx-SCC Results Into Clinical Decision Making for Cutaneous Squamous Cell Carcinoma Patients With One or More Risk Factors (Businesswire)
19.05.21		Castle Biosciences to Participate in the Oppenheimer MedTech, Tools, & Diagnostics Summit (Businesswire)
11.05.21		Tiffany Olson, Seasoned Diagnostics Executive, Joins Castle Biosciences’ Board of Directors (Businesswire)
10.05.21		Castle Biosciences Announces First Quarter 2021 Results (Businesswire)
10.05.21		Castle Biosciences Announces Pipeline Initiative to Develop Genomic Test Targeting Systemic Therapy Response in Patients with Psoriasis, Atopic Dermatitis and Related Conditions (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Tesla-CFO schlägt Alarm: Werden Trump-Zölle zur Bedrohung?

Ausblick: Super Micro Computer vermeldet Zahlen zum jüngsten Quartal

Apple überrascht: Neues iPhone SE könnte früher kommen als erwartet

So bewegt Trumps Zollpolitik den Goldpreis und die Newmont Mining- & Barrick Gold-Aktien

Palantir-Aktie nach Kursrally: Lohnt sich jetzt noch ein Einstieg?

Pierer-Mobility-Aktie in Grün: AR-Chef Zöchling könnte als KTM-Investor mitmischen

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	12.02.2025 06:50
Kaufwert:	EUR
	Hinzufügen Speichern